Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Systane® Balance in Dry Eye Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sign informed consent and willing and able to attend all study visits;~* Dry eye in both eyes diagnosed by an ophthalmologist;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential who are pregnant or breastfeeding;~* Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in the study;~* Ocular surgery or ocular trauma requiring medical or pharmacological treatment within 1 year of Screening;~* Use of topical ocular prescription or non-prescription medications, RESTASIS or topical ocular steroids within 14 days of Screening;~* Use of any artificial tears/gels/lubricants/rewetting drops within 4 hours of Screening;~* Contact lens wear within 1 week of Screening and/or unwillingness to discontinue contact lens wear for the duration of the study;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Systane Balance (Type: EXPERIMENTAL): Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).